Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | PNMT | P11086 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.36 |
| ▸ | ABAT | P80404 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20182944 | 0.83 | GABRA1 (0.55) | TAAR1PNMTGABRA1GABRB2HMGB1 | |
| SCHEMBL2051870 | 0.77 | GABRA1 (0.70) | TAAR1GABRA1GABRB2 | |
| SCHEMBL4902607 | 0.76 | TAAR1 (0.48) | TAAR1PNMTIDO1DPP4ASH1L | |
| SCHEMBL366656 | 0.76 | ADAMTS4 (0.52) | TAAR1PNMTGABRA1GABRB2IDO1 | |
| SCHEMBL1765174 | 0.75 | — | — | |
| SCHEMBL24349403 | 0.74 | GABRA1 (0.46) | TAAR1PNMTGABRA1GABRB2HMGB1 | |
| SCHEMBL13977269 | 0.74 | TAAR1 (0.46) | TAAR1PNMTIDO1DPP4LOXL2 | |
| SCHEMBL18769305 | 0.74 | TAAR1 (0.46) | TAAR1PNMTIDO1DPP4ASH1L | |
| SCHEMBL20844632 | 0.74 | PNMT (0.60) | TAAR1PNMTIDO1DPP4LOXL2 | |
| Hydrochloric Acid SCHEMBL1998632 | 0.74 | ADAMTS4 (0.50) | TAAR1PNMTGABRA1GABRB2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019057946-A1 | MULTI-CYCLIC AROMATIC COMPOUNDS AS FACTOR D INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-28 | — | — | WO | disclosed |
| US-9073961-B2 | Substitution derivatives of N6 -benzyladenosine-5′-monophosphate, methods of preparation thereof, use thereof as medicaments, and therapeutic preparations containing these compounds | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2015-07-07 | — | — | US | disclosed |
| EP-2563801-B1 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5´-MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATION CONTAINING THESE COMPOUNDS | Univerzita Palackého v Olomouci (CZ) | 2014-09-24 | — | — | EP | disclosed |
| US-20130040908-A1 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5' -MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATIONS CONTAINING THESE COMPOUNDS | BIOAPEX, S.R.O. (CZ) | 2013-02-14 | — | — | US | disclosed |
| US-4029816-A | ANTIHYPERTENSIVE, DIURETIC, SALURETIC | MERCK & CO., INC. (US) | 1977-06-14 | — | — | US | disclosed |
| US-4029816-A | ANTIHYPERTENSIVE, DIURETIC, SALURETIC | MERCK & CO., INC. (US) | 1977-06-14 | — | — | US | disclosed |
| US-4029816-A | ANTIHYPERTENSIVE, DIURETIC, SALURETIC | MERCK & CO., INC. (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040908-A1 | SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5' -MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATIONS CONTAINING THESE COMPOUNDS | MTAP, RNMT, NUDT1 | TAAR1 3238/4885PNMT 300/4885GABRA1 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.